Probiotics for managing patients after bowel preparation for colonoscopy: an interventional, double-arm, open, randomized, multi-center, and national study (COLONSTUDY).

IF 1.9 Q3 GASTROENTEROLOGY & HEPATOLOGY
Salvatore E Aragona, Cristiano Spada, Luca DE Luca, Elena Aragona, Giorgio Ciprandi
{"title":"Probiotics for managing patients after bowel preparation for colonoscopy: an interventional, double-arm, open, randomized, multi-center, and national study (COLONSTUDY).","authors":"Salvatore E Aragona, Cristiano Spada, Luca DE Luca, Elena Aragona, Giorgio Ciprandi","doi":"10.23736/S2724-5985.24.03630-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bowel preparation (BP) for colonoscopy induces significant changes in gut microbiota, causing dysbiosis that, in turn, elicits intestinal symptoms. Consequently, probiotics may counterbalance the disturbed microbiota after BP. So, probiotics may restore microbiota homeostasis.</p><p><strong>Methods: </strong>The current study evaluated the efficacy and safety of Abincol<sup>®</sup>, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions living cells), and Lactobacillus delbrueckii LDD01 (200 millions living cells), Patients were randomized in two groups (2:1). Group A took one stick/daily for four weeks after colonoscopy. Group B was considered as control. Patients were evaluated at baseline (T0) and after one (T1), two (T2), and four (T3) weeks. The severity of symptoms was measured by patients using a Visual Analog Scale.</p><p><strong>Results: </strong>Abincol<sup>®</sup> significantly diminished the presence and the severity of intestinal symptoms at T2 and even more at T3. All patients well tolerated the probiotic mixture.</p><p><strong>Conclusions: </strong>The present study suggests that Abincol<sup>®</sup> may be considered an effective and safe therapeutic option in managing patients undergoing BP. The course should last one month.</p>","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":"70 2","pages":"187-196"},"PeriodicalIF":1.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-5985.24.03630-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bowel preparation (BP) for colonoscopy induces significant changes in gut microbiota, causing dysbiosis that, in turn, elicits intestinal symptoms. Consequently, probiotics may counterbalance the disturbed microbiota after BP. So, probiotics may restore microbiota homeostasis.

Methods: The current study evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions living cells), and Lactobacillus delbrueckii LDD01 (200 millions living cells), Patients were randomized in two groups (2:1). Group A took one stick/daily for four weeks after colonoscopy. Group B was considered as control. Patients were evaluated at baseline (T0) and after one (T1), two (T2), and four (T3) weeks. The severity of symptoms was measured by patients using a Visual Analog Scale.

Results: Abincol® significantly diminished the presence and the severity of intestinal symptoms at T2 and even more at T3. All patients well tolerated the probiotic mixture.

Conclusions: The present study suggests that Abincol® may be considered an effective and safe therapeutic option in managing patients undergoing BP. The course should last one month.

在结肠镜检查肠道准备后使用益生菌管理患者:一项干预性、双臂、开放、随机、多中心和全国性研究(COLONSTUDY)。
背景:结肠镜检查前的肠道准备(BP)会引起肠道微生物群的显著变化,导致菌群失调,进而引发肠道症状。因此,益生菌可以平衡肠道准备术后紊乱的微生物群。因此,益生菌可恢复微生物群平衡:本研究评估了 Abincol® 的有效性和安全性,它是一种口服营养保健品,含有植物乳杆菌 LP01(10 亿活细胞)、乳酸乳杆菌亚种 cremoris LLC02(8 亿活细胞)和德尔布鲁贝克乳杆菌 LDD01(2 亿活细胞)的益生菌混合物。A 组在结肠镜检查后每天服用一根,连续服用四周。B 组为对照组。患者在基线(T0)、一周(T1)、两周(T2)和四周(T3)后接受评估。患者使用视觉模拟量表测量症状的严重程度:结果:阿滨珂®在T2阶段明显减轻了肠道症状的出现和严重程度,在T3阶段减轻得更多。所有患者都能很好地耐受益生菌混合物:本研究表明,阿欣高® 可被视为治疗接受 BP 的患者的一种有效而安全的选择。疗程应持续一个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信